Mitä Frelii tekee? Frelii Inc is an emerging company in the field of personalized healthcare and diagnostics. The company, which opened its headquarters in Salt Lake City, Utah, USA in 2016, aims to provide personalized therapies and diagnoses for each patient based on DNA tests and computer analysis. The company has a specialized team of scientists, doctors, engineers, and IT experts who have come together to develop advanced technologies that have the potential to revolutionize healthcare. Business model: Frelii's business model is focused on providing personalized diagnoses and therapies for each patient. The company can achieve this through a combination of DNA testing, genome data analysis, and the use of AI algorithms. With a wide range of tests and analyses, Frelii can unleash the full potential of high-tech diagnostics and minimally invasive therapy. History: The company was founded by CEO Ian Jenkins and Dr. David R. Koepsell (formerly President of Upturn). Their goal was to decipher the human genome and use the results of genome tests to provide precise diagnoses and therapies. Since then, the company has focused on understanding the complexity of the human genome and maximizing the capabilities of personalized medicine and diagnostics. Offered divisions and products: Frelii offers a range of personalized DNA tests and analyses. These tests examine an individual's entire genome to gain information about personal risks for diseases, allergies, and other medical conditions. These results are then analyzed by a team of scientists and doctors who create personalized recommendations for diet, lifestyle, and medical therapy. Frelii also has its own software platform for processing genome data and offers personalized research and development programs for clinical studies, association analyses, and genome-wide screens. The company is also a leader in the development of therapy and diagnostic methods based on CRISPR/Cas9 and other high-tech technologies. The Frelii team is committed to improving the quality of medical care and facilitating access to personalized healthcare methods. Frelii's DNA tests have already led to a variety of patients being able to discover their disease risks for themselves and consciously engage in adapting their lifestyles. The company aims to bring research efforts and the practical implementation of personalized medicine to the forefront. Conclusion: Frelii is at the forefront of personalized genomic research and aims to take healthcare to a whole new level. The company offers personalized DNA tests and analyses, as well as the analysis of genome data to provide precise diagnoses and therapies. Frelii has its own software platform for processing genome data that engages medical researchers, doctors, and patients alike. It remains to be seen how this emerging company will redefine personalized medical care. Frelii on yksi Eurpooliin suosituimmista yhtiöistä.